| pubmed-article:20482245 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:20482245 | lifeskim:mentions | umls-concept:C2709213 | lld:lifeskim |
| pubmed-article:20482245 | lifeskim:mentions | umls-concept:C0006347 | lld:lifeskim |
| pubmed-article:20482245 | lifeskim:mentions | umls-concept:C0936012 | lld:lifeskim |
| pubmed-article:20482245 | lifeskim:mentions | umls-concept:C0013232 | lld:lifeskim |
| pubmed-article:20482245 | lifeskim:mentions | umls-concept:C0004950 | lld:lifeskim |
| pubmed-article:20482245 | pubmed:issue | 2 | lld:pubmed |
| pubmed-article:20482245 | pubmed:dateCreated | 2010-6-10 | lld:pubmed |
| pubmed-article:20482245 | pubmed:abstractText | This article aims to calculate the impact of orphan drugs on the Belgian drug budget in 2008 and to forecast its impact over the following 5 years. | lld:pubmed |
| pubmed-article:20482245 | pubmed:language | eng | lld:pubmed |
| pubmed-article:20482245 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:20482245 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:20482245 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:20482245 | pubmed:issn | 1941-837X | lld:pubmed |
| pubmed-article:20482245 | pubmed:author | pubmed-author:CleemputIrina... | lld:pubmed |
| pubmed-article:20482245 | pubmed:author | pubmed-author:DenisAlainA | lld:pubmed |
| pubmed-article:20482245 | pubmed:author | pubmed-author:SimoensSteven... | lld:pubmed |
| pubmed-article:20482245 | pubmed:author | pubmed-author:MergaertLutL | lld:pubmed |
| pubmed-article:20482245 | pubmed:author | pubmed-author:FostierChrist... | lld:pubmed |
| pubmed-article:20482245 | pubmed:issnType | Electronic | lld:pubmed |
| pubmed-article:20482245 | pubmed:volume | 13 | lld:pubmed |
| pubmed-article:20482245 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:20482245 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:20482245 | pubmed:pagination | 295-301 | lld:pubmed |
| pubmed-article:20482245 | pubmed:meshHeading | pubmed-meshheading:20482245... | lld:pubmed |
| pubmed-article:20482245 | pubmed:meshHeading | pubmed-meshheading:20482245... | lld:pubmed |
| pubmed-article:20482245 | pubmed:meshHeading | pubmed-meshheading:20482245... | lld:pubmed |
| pubmed-article:20482245 | pubmed:meshHeading | pubmed-meshheading:20482245... | lld:pubmed |
| pubmed-article:20482245 | pubmed:meshHeading | pubmed-meshheading:20482245... | lld:pubmed |
| pubmed-article:20482245 | pubmed:meshHeading | pubmed-meshheading:20482245... | lld:pubmed |
| pubmed-article:20482245 | pubmed:meshHeading | pubmed-meshheading:20482245... | lld:pubmed |
| pubmed-article:20482245 | pubmed:year | 2010 | lld:pubmed |
| pubmed-article:20482245 | pubmed:articleTitle | Budget impact analysis of orphan drugs in Belgium: estimates from 2008 to 2013. | lld:pubmed |
| pubmed-article:20482245 | pubmed:affiliation | Yellow Window Management Consultants, Antwerp, Belgium. | lld:pubmed |
| pubmed-article:20482245 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:20482245 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
